John L. Armstrong Jr. Net Worth

The estimated Net Worth of Jr. John L. Armstrong is at least $1.08 Milione dollars as of 14 August 2020. Mr Armstrong owns over 27,500 units of CorMedix Inc stock worth over $669,427 and over the last 8 years he sold CRMD stock worth over $0. In addition, he makes $407,801 as Exec. VP for Technical Operations at CorMedix Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Jr CRMD stock SEC Form 4 insiders trading

Mr has made over 7 trades of the CorMedix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 27,500 units of CRMD stock worth $116,050 on 14 August 2020.

The largest trade he's ever made was buying 250,000 units of CorMedix Inc stock on 29 November 2018 worth over $362,500. On average, Mr trades about 27,261 units every 75 days since 2017. As of 14 August 2020 he still owns at least 96,878 units of CorMedix Inc stock.

You can see the complete history of Mr Armstrong stock trades at the bottom of the page.

Mr. John L. Armstrong Jr. biography

John L. Armstrong Jr. is the Exec. VP for Technical Operations at CorMedix Inc.

What is the salary of Mr Jr?

As the Exec. VP for Technical Operations of CorMedix Inc, the total compensation of Mr Jr at CorMedix Inc is $407,801. There are 7 executives at CorMedix Inc getting paid more, with Khoso Baluch having the highest compensation of $1,795,830.

How old is Mr Jr?

Mr Jr is 76, he's been the Exec. VP for Technical Operations of CorMedix Inc since . There are no older and 13 younger executives at CorMedix Inc.

What's Mr Jr's mailing address?

Jr's mailing address filed with the SEC is C/O CORMEDIX INC., 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at CorMedix Inc

Over the last 15 years, insiders at CorMedix Inc have traded over $693,980 worth of CorMedix Inc stock and bought 2,651,866 units worth $3,532,566 . The most active insiders traders include Mehmood Khan, Gary A. Gelbfish e Brian Lenz. On average, CorMedix Inc executives and independent directors trade stock every 30 days with the average trade being worth of $199,105. The most recent stock trade was executed by Joseph Todisco on 13 March 2024, trading 13,561 units of CRMD stock currently worth $50,718.

What does CorMedix Inc do?

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.

Complete history of Mr Armstrong stock trades at CorMedix Inc

CorMedix Inc executives and stock owners

CorMedix Inc executives and other stock owners filed with the SEC include:

• Khoso Baluch,
  Chief Executive Officer, Interim Principal Accounting Officer, Director
• Phoebe Mounts,
  Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal
• Elizabeth Masson,
  Executive Vice President - Head of Clinical Operations
• Khoso Baluch,
  CEO & Director
• Dr. Phoebe Mounts Esq.,
  Exec. VP, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal
• John Armstrong,
  Executive Vice President - Technical Operations
• Elizabeth Masson-Hurlburt,
  Exec. VP & Head of Clinical Operations
• John L. Armstrong Jr.,
  Exec. VP for Technical Operations
• Alan Dunton,
  Independent Director
• Myron Kaplan,
  Independent Chairman of the Board
• Steven Lefkowitz,
  Independent Director
• Janet Dillione,
  Independent Director
• Gregory Duncan,
  Director
• Paulo Costa,
  Director
• Matthew David,
  Chief Financial Officer, Executive Vice President
• Thomas Nusbickel,
  Exec. VP & Chief Commercial Officer
• Dr. Paul Chew M.D.,
  Acting Chief Medical Officer
• Dr. Paul Chew,
  Acting Chief Medical Officer
• Dr. Matthew T. David M.D.,
  Exec. VP & CFO
• Judith R Abrams,
  Chief Medical Officer
• Robert W. Cook,
  Chief Financial Officer
• Taunia Markvicka,
  Director
• Antony Pfaffle,
  Director
• Randy Milby,
  Chief Operating Officer
• Cora M Tellez,
  Director
• Mehmood Khan,
  
• Michael W George,
  Director
• Gary A. Gelbfish,
  Director
• James Lefkowitz,
  Director
• Bami Bastani,
  Director
• Timothy M Hofer,
  Secretary
• Mark T. Houser,
  Chief Medical Officer
• John C. Houghton,
  President and CEO
• Mark A. Klausner,
  Chief Medical Officer
• Russell H Ellison,
  Director
• Robert A Stewart,
  
• Matthew Duffy,
  Director
• Harry O'grady,
  Chief Financial Officer
• Richard Cohen,
  Director
• Development Inc Pharmabio,
  10% owner
• Brian Lenz,
  Chief Financial Officer
• Thomas Nusbickel,
  EVP, Chief Commercial Officer
• Joseph Todisco,
  Chief Executive Officer
• Kaufman Beth Zelnick,
  Chief Legal Officer
• Erin Mistry,
  Chief Commercial Officer